6533b873fe1ef96bd12d5649
RESEARCH PRODUCT
Comparison of roxatidine and ranitidine in the treatment of refractory duodenal ulcer
M. DonatelliM.g. CataldoD. Brancatosubject
Pharmacologymedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentGastroenterologyGroup BRanitidineDuodenal ulcermedicine.anatomical_structureHistamine H2 receptorRefractoryInternal medicineDuodenummedicineRoxatidine acetatePharmacology (medical)businessmedicine.drugdescription
Abstract Fourteen patients with duodenal ulcer not healed after treatment with ranitidine at the standard dosage of 300 mg/day for 12 weeks were enrolled in the study. Eight patients were treated with roxatidine acetate, 150 mg/day, for 8 weeks (group A); six patients received treatment with ranitidine, 600 mg/day, for 8 weeks (group B). Efficacy of treatment was evaluated on the basis of reduction of ulcer pain, lowering of maximal acid output (MAO) levels, and cicatrization of ulcer lesion. The patients treated with roxatidine showed a significant reduction in MAO levels after 4 weeks, whereas the patients treated with ranitidine showed a significant reduction in MAO levels after 8 weeks. The differences in reduction of ulcer pain or cicatrization percentage were not significant between groups.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 1994-04-01 | Current Therapeutic Research |